VEA
NWBO

Virtus ETF Advisers’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Virtus ETF Advisers’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-78,696
Closed -$115K – 161
2016
Q1 		$115K Buy
+78,696
New +$155K 0.16% 141

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtus ETF Advisers's NWBO Position: Q2 2016 in Review

Virtus ETF Advisers sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 78,696 shares — an estimated $115K sold.

Virtus ETF Advisers first reported a position in NWBO in Q1 2016 and held it in 1 quarter. The position peaked at $115K in Q1 2016. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

  • Virtus ETF Advisers reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
  • Virtus ETF Advisers sold 78,696 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $115K.
  • Virtus ETF Advisers first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2016 and held it in 1 quarter.
  • Virtus ETF Advisers's Northwest Biotherapeutics, Inc. Common stock position peaked at $115K in Q1 2016.
  • 64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on Virtus ETF Advisers's 13F filing for Q2 2016, filed 15 Aug 2016.